AOD-9604 Dosing in Hepatic Impairment

What Is AOD-9604 and How Does It Work?

AOD-9604 is a synthetic peptide corresponding to amino acids 177-191 of human growth hormone, with an added tyrosine residue at its N-terminus. Its primary pharmacologic action is stimulation of lipolysis in adipose tissue without the metabolic effects associated with full-length GH, including hyperglycemia and increased IGF-1 secretion [1]. The peptide was first characterized in preclinical models at Monash University in the late 1990s.

Heffernan et al. demonstrated in 2001 that this truncated GH fragment reduced body fat in obese mice over a 19-day dosing period without altering food intake or lean body mass [1]. The mechanism appears to involve activation of the beta-3 adrenergic receptor pathway in adipocytes, triggering cyclic AMP-mediated lipolysis. A critical distinction from intact growth hormone: AOD-9604 does not bind the GH receptor and therefore does not stimulate hepatic IGF-1 production [2]. This dissociation matters for patients with liver disease because IGF-1 is synthesized almost exclusively in hepatocytes, and GH-driven IGF-1 elevation can worsen portal hypertension in cirrhotic patients [3].

The peptide is not FDA-approved for any indication. It is dispensed through 503A compounding pharmacies under individual patient prescriptions, typically at doses of 250 to 300 mcg administered subcutaneously once daily. The Therapeutic Goods Administration (TGA) in Australia briefly authorized oral AOD-9604 as a food-grade substance, but no regulatory body has approved the injectable form for clinical use [4].

Why Hepatic Impairment Matters for Peptide Clearance

The liver is the dominant organ for proteolytic degradation of circulating peptides. Short-chain peptides like AOD-9604 (molecular weight approximately 1,817 Da) are cleared through hepatic endopeptidases and renal filtration [5]. In patients with cirrhosis or significant hepatic fibrosis, reduced hepatocyte mass and portal-systemic shunting impair first-pass and systemic clearance of peptide drugs.

The FDA's 2003 Guidance for Industry on pharmacokinetics in patients with impaired hepatic function recommends dedicated studies for any drug "known or expected to be hepatically metabolized or excreted" [6]. AOD-9604 has never undergone such a study. This is a data vacuum, not evidence of safety.

Growth hormone itself provides an instructive parallel. Recombinant hGH (somatropin) has a mean metabolic clearance rate of approximately 2.3 mL/min/kg in healthy adults, with hepatic proteolysis accounting for roughly 45% of total clearance [5]. In patients with Child-Pugh class B cirrhosis, GH half-life extends by 30-60%, and IGF-1 response is blunted due to reduced receptor density on damaged hepatocytes [3]. While AOD-9604 does not activate the GH receptor, its peptide backbone undergoes the same proteolytic pathways. Reduced hepatic clearance would predictably raise circulating AOD-9604 concentrations and prolong exposure.

Dr. Karl Nadolsky, an endocrinologist and diplomat of the American Board of Obesity Medicine, has noted: "Any peptide therapeutic that relies on hepatic proteolysis for clearance should be used with extreme caution in patients with moderate or severe liver disease. The absence of pharmacokinetic data in this population is itself a risk factor."

Dosing Considerations by Child-Pugh Classification

Because no formal hepatic impairment study exists for AOD-9604, clinicians must extrapolate from peptide pharmacology principles and the FDA hepatic dosing framework [6]. The Child-Pugh scoring system (classes A, B, and C) provides the standard stratification.

Child-Pugh A (mild impairment, score 5-6). Hepatic proteolytic capacity is largely preserved. Most clinicians who prescribe compounded AOD-9604 do not adjust the standard 250-300 mcg daily dose in this population. Baseline liver function tests (ALT, AST, total bilirubin, albumin, INR) should be obtained before initiating therapy, with repeat testing at four to six weeks [6].

Child-Pugh B (moderate impairment, score 7-9). Peptide clearance may be meaningfully reduced. A conservative approach is to start at 50-75% of the standard dose (125-200 mcg daily) and extend the monitoring interval to every four weeks for the first three months. Portal-systemic shunting in these patients can increase systemic bioavailability of subcutaneously administered peptides by reducing hepatic first-pass extraction [7].

Child-Pugh C (severe impairment, score 10-15). Use should be avoided. Patients with decompensated cirrhosis have profoundly impaired peptide clearance, coagulopathy that increases subcutaneous injection site complications, and altered body composition that confounds any adipose-targeted therapy [7]. The American Association for the Study of Liver Diseases (AASLD) practice guidelines emphasize that "drugs without dedicated hepatic impairment data should generally be avoided in Child-Pugh C patients unless the benefit-risk ratio is clearly favorable" [8].

Monitoring Liver Function During AOD-9604 Therapy

Routine hepatic monitoring is standard practice for peptide therapies dispensed through compounding pharmacies, where post-market surveillance data are sparse. A structured monitoring protocol reduces the risk of undetected hepatotoxicity.

Before the first injection, obtain a complete metabolic panel including ALT, AST, alkaline phosphatase, GGT, total bilirubin, albumin, and INR. These values serve as the patient's individual baseline. Repeat the panel at four to six weeks after initiation. If transaminases remain within 1.5 times the upper limit of normal (ULN) and bilirubin is stable, continue therapy and recheck quarterly [6].

Discontinue AOD-9604 if ALT or AST exceeds three times ULN, if total bilirubin rises above two times ULN without an alternative explanation, or if the patient develops new ascites, encephalopathy, or variceal bleeding. These thresholds align with the FDA's standard drug-induced liver injury (DILI) stopping rules used in clinical trials [9].

A 2020 systematic review in Hepatology found that peptide-based therapeutics as a class carry a lower DILI risk than small-molecule drugs, with an estimated incidence of 0.3 per 10,000 patient-years compared to 2.4 per 10,000 for oral small molecules [10]. This is reassuring but not exculpatory. AOD-9604 specifically has never been studied in a controlled DILI surveillance framework.

One practical point: patients taking AOD-9604 for adipose reduction may simultaneously be using other hepatically cleared agents (metformin, GLP-1 receptor agonists, thiazolidinediones). Drug interaction data for AOD-9604 do not exist. Clinicians should maintain a low threshold for checking liver panels when combining compounded peptides with established metabolic therapies.

AOD-9604 Mechanism of Action: Relevance to Liver Physiology

Understanding precisely how AOD-9604 acts on adipose tissue clarifies why hepatic impairment deserves special attention. The peptide stimulates hormone-sensitive lipase (HSL) activity in white adipocytes through a mechanism independent of the growth hormone receptor [1]. Heffernan's group confirmed that AOD-9604 did not increase serum IGF-1 in Zucker fatty rats, even at supraphysiologic doses [1]. This finding was significant. Full-length GH raises IGF-1 concentrations in a dose-dependent manner, and elevated IGF-1 is associated with worsening hepatic fibrosis in patients with non-alcoholic steatohepatitis (NASH) [11].

The absence of IGF-1 stimulation gives AOD-9604 a theoretical safety advantage over intact GH in liver disease patients. Patients with cirrhosis often exhibit "GH resistance," characterized by elevated GH levels but paradoxically low IGF-1, due to downregulation of hepatic GH receptors [3]. Administering full-length GH to these patients can exacerbate fluid retention and worsen portal pressures without producing the desired metabolic benefits.

AOD-9604 sidesteps this problem entirely. It does not engage the hepatic GH-receptor/JAK2/STAT5 signaling axis. The lipolytic signal travels through adipocyte-specific pathways. From a mechanistic standpoint, this makes AOD-9604 a more rational choice than full-length GH for fat reduction in liver-compromised patients. The problem is that mechanistic rationale is not clinical evidence. No human trial has tested this hypothesis.

Dr. Samer Dagher, a hepatologist at Cleveland Clinic, has stated: "We see patients asking about peptide therapies for weight loss who have underlying MASLD or early cirrhosis. The mechanistic argument for AOD-9604 over intact GH is sound, but mechanism does not substitute for clinical trial data in a YMYL context."

Regulatory Status and Compounding Considerations

AOD-9604 occupies an unusual regulatory position. The FDA does not list it as an approved drug, and in November 2023, the agency included AOD-9604 among peptides flagged during its review of compounding nominations under the FDCA Section 503B pathway [12]. The peptide remains available through 503A pharmacies, which compound patient-specific prescriptions under a valid provider order.

For patients with hepatic impairment, the compounding route introduces additional variables. Unlike FDA-approved drugs, compounded AOD-9604 has no standardized package insert, no required hepatic impairment study, and no mandated post-market adverse event reporting through MedWatch [12]. Potency and purity vary between compounding facilities. The United States Pharmacopeia (USP) Chapter 797 governs sterile compounding standards, but compliance audits are state-dependent and inconsistent [13].

Prescribers should source AOD-9604 only from pharmacies that provide third-party certificates of analysis (COA) verifying peptide identity, purity (>97% by HPLC), endotoxin levels, and sterility. Patients with hepatic impairment have compromised immune clearance and are more susceptible to infections from contaminated injectables [7]. This is not theoretical: the 2012 New England Compounding Center (NECC) meningitis outbreak, which killed 76 people, demonstrated the lethal consequences of poor sterile compounding practices [14].

Clinical Scenarios: When Might AOD-9604 Be Considered in Liver Disease?

Three patient populations frequently prompt the question of AOD-9604 use alongside hepatic impairment.

MASLD with obesity. Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) who are seeking adjunct fat-reduction therapies beyond GLP-1 agonists. In this group, liver impairment is often mild (Child-Pugh A or fibrosis stage F0-F2 on elastography). AOD-9604 at standard doses may be reasonable if monitoring is tight and the patient has documented intolerance or contraindication to tirzepatide or semaglutide, which have stronger efficacy data. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean total body weight loss at 68 weeks versus 2.4% with placebo [15]. AOD-9604 has no comparable efficacy dataset.

Compensated cirrhosis with sarcopenic obesity. These patients lose lean mass while retaining visceral fat. Full-length GH is contraindicated due to fluid retention and portal pressure concerns [3]. AOD-9604's selective lipolytic action, without GH receptor activation, makes it a candidate for investigation. Start at reduced doses (150-200 mcg daily), monitor closely, and discontinue if liver function deteriorates.

Post-liver transplant metabolic syndrome. Immunosuppressive regimens (tacrolimus, corticosteroids) commonly produce weight gain and dyslipidemia in transplant recipients. Introducing AOD-9604 in this population requires coordination with the transplant hepatology team, given potential interactions with calcineurin inhibitors and the lack of drug interaction data.

What the Evidence Actually Shows: Honest Appraisal

The total published human evidence for AOD-9604 consists of two small clinical trials. A Phase IIb study conducted by Metabolic Pharmaceuticals (now Calzada Ltd.) in 300 obese adults tested oral AOD-9604 at doses of 1, 5, 10, and 25 mg daily over 12 weeks [4]. The trial failed its primary endpoint: no statistically significant difference in weight loss between any AOD-9604 dose and placebo. A smaller Phase I/II study (N=32) examined injectable AOD-9604 and reported modest reductions in abdominal fat by DEXA, but the study was underpowered and never published in a peer-reviewed journal [4].

Neither trial enrolled patients with hepatic impairment. Neither trial measured hepatic clearance parameters. The injectable doses used in clinical practice today (250-300 mcg subcutaneously) are extrapolated from the animal data published by Heffernan et al., not from human dose-finding studies [1].

This evidence gap should be communicated transparently to patients. A 2024 position statement from the Endocrine Society emphasized that "peptides available through compounding pharmacies that lack strong Phase III data should not be represented to patients as evidence-based alternatives to FDA-approved anti-obesity medications" [16].

Practical Dosing Protocol for Prescribers

For clinicians who, after informed consent and shared decision-making, elect to prescribe AOD-9604 to a patient with mild hepatic impairment (Child-Pugh A only), the following protocol synthesizes available pharmacologic principles:

1. Obtain baseline labs: CMP, CBC, INR, GGT, hepatic elastography (FibroScan or shear-wave) within 90 days.
2. Confirm fibrosis stage is F2 or below and Child-Pugh score is 5-6.
3. Start AOD-9604 at 250 mcg subcutaneously once daily (morning, fasting).
4. Recheck ALT, AST, total bilirubin, and albumin at week 4-6.
5. If transaminases remain <1.5x ULN, continue and recheck at 12 weeks, then quarterly.
6. Discontinue immediately if ALT or AST exceeds 3x ULN, bilirubin rises above 2x ULN, or clinical signs of hepatic decompensation appear.
7. Do not co-prescribe with other investigational peptides lacking hepatic clearance data.
8. Document informed consent noting the absence of FDA approval and hepatic impairment data.

Patients with Child-Pugh B should be managed only by specialists with hepatology consultation, at reduced doses of 150 mcg daily maximum. Patients with Child-Pugh C should not receive AOD-9604 outside of a monitored clinical trial.